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PENGKLONAN, PENGEKSPRESIAN DAN PENULENAN ANTIGEN 
REKOMBINAN Toxocara canis (rTES-26, rTES-32, rTES-120) DAN 
PEMBANGUNAN UJIAN SERODIAGNOSTIK BAGI TOKSOKARIASIS 
Abstrak
Serodiagnosis  rutin  untuk  penyakit  toksokariasis  pada  manusia  adalah  berdasarkan  kit 
ELISA-IgG  tak-langsung  yang  menggunakan  antigen  ekskretori-sekretori  natif  daripada 
Toxocara  canis.  Walau  bagaimanapun,  asai  tersebut  mempunyai  spesifisiti  yang  rendah, 
terutamanya untuk kegunaan di negara tropika yang mempunyai pelbagai jangkitan parasit. 
Dalam usaha untuk meningkatkan kejituan ujian diagnostik bagi penyakit ini, asai ELISA-
IgG4 telah dibangunkan dengan menggunakan tiga antigen rekombinan. 
Dalam kajian ini, DNA rekombinan T. canis yang mengkodkan antigen rekombinan 
rTES-26, rTES-32 dan rTES-120 dihasilkan dengan mengklonkan kerangka bacaan terbuka 
gen  masing-masing  melalui  kaedah “reverse-transcriptase-PCR”  (RT-PCR)  menggunakan 
mRNA  yang  diekstrak  daripada  kultur  larva  T.  canis peringkat  kedua  ke  dalam vektor 
PCR2.1  TOPO.  Analisis  jujukan  menunjukkan  TOPO/TES-32  and  TOPO/TES-120 
mempunyai  persamaan  100% dengan jujukan  yang  dilaporkan  dalam “GenBank”,  tetapi 
fragmen  gen  TOPO/TES-26  mempunyai  empat  mutasi.  Selepas  kesemua  mutasi  dalam 
TOPO/TES-26 diperbaiki, TES-26 dan TES-32 kemudiannya disubklonkan ke dalam vektor 
19
ekspresi yang mempunyai penanda GST, manakala TES-120 disubklonkan ke dalam vektor 
yang mempunyai penanda histidin, dan kesemuanya diekspreskan di dalam hos ekspresi E.  
coli BL21(DE3).  
Protein rekombinan  tersebut  kemudiannya  ditulenkan secara  natif  dengan kaedah 
kromatografi  afiniti  menggunakan  resin  GST  dan  His-Trap  kerana  protein  rekombinan 
tersebut  banyak  terhasil  dalam bentuk  yang  terlarut.  Protease  tapak  spesifik,  Factor  Xa, 
digunakan untuk membuang penanda GST dalam protein rekombinan TES-26 (rTES-26) dan 
TES-32 (rTES-32). Analisis blot Western menunjukkan antigen rekombinan tersebut adalah 
reaktif  dan  spesifik  secara  imunologik.  Serum  daripada  pesakit  toksokariasis  yang 
mempunyai  antibodi  IgG4  dapat  mengenalpasti  antigen  rekombinan  tersebut,  manakala 
serum daripada pesakit jangkitan lain dan individu sihat adalah tidak reaktif.
Apabila  ketiga-tiga antigen rekombinan diuji  dengan ELISA yang spesifik  untuk 
immunoglobulin  klas  IgM  dan  IgE  dan  subklas  IgG  (IgG1-IgG4),  keputusan  jelas 
menunjukkan  bahawa  hanya  asai  IgG4  memberikan  spesifisiti  yang  baik.  Keupayaan 
diagnostik  setiap antigen rekombinan  tulen dan rTES-30USM (dihasilkan sebelum ini  di 
dalam makmal  kami)  seterusnya  dinilai  dengan  asai  ELISA-IgG4  menggunakan  sampel 
serum  sebanyak  242  yang  termasuk  30  pesakit  toksokariasis  dengan  bukti  klinikal, 
hematologi  dan  serologi.  Kedua-dua  asai  rTES-26  dan  rTES-32  ELISA  menunjukkan 
sensitiviti 80.0%; manakala rTES-120 ELISA-IgG4 menunjukkan sensitiviti 93.3.0%, sama 
seperti  yang  telah  dilaporkan  sebelum  ini  untuk  rTES-30USM  ELISA-IgG4.  Tahap 
sensitiviti  rTES-120/rTES-30USM  ELISA-IgG4  adalah  lebih  tinggi  secara  signifikan 
daripada rTES-26/  rTES-32 ELISA-IgG4 (p<0.001).  Walau bagaimanapun,  perbandingan 
min O.D 30 sampel toksokariasis di antara asai IgG4 dengan menggunakan empat antigen 
recombinan tidak menunjukkan perbezaan yang signifikan  (p>0.05). Pada tahap signifikan 
p<0.05,  tiada  perbezaan  yang  signifikan  di  antara  spesifisiti  rTES-26  dan  rTES-120 
(p=0.059), di antara rTES-26 dan rTES-30USM atau di antara rTES-30USM dan rTES-120.
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Dalam  asai  terakhir,  rTES-32  tidak  dimasukkan  kerana  ia  tidak  menunjukkan 
sensitiviti  dan  spesifisiti  yang  lebih  baik  daripada  rTES-26.  Malah  rTES-30USM 
dimasukkan kerana sensitivitinya yang tinggi dan pengesanan 100% kes toksokariasis dapat 
dicapai  apabila  keputusan  asai  IgG4  menggunakan  rTES-30USM  dan  rTES-120 
digabungkan. 
Kesimpulannya,  asai  terakhir  yang sensitif  (80.0% - 93.3%) dan spesifik (92.0% 
-96.2%)  untuk  pengesanan  penyakit  toksokariasis  telah  berjaya  dibangunkan  dengan 
menggunakan tiga telaga yang bersebelahan, setiap satunya disalut dengan rTES-26, rTES-
30USM dan rTES-120. Kajian ini ádalah novel dalam beberapa aspek iaitu ia adalah yang 
pertama  melaporkan  penggunaan  pelbagai  antigen  rekombinan  untuk  serodiagnosis 
toksokariasis; penggunaan rTES-26 (dan rTES-32) dalam serodiagnosis jangkitan toksokara; 
penggunaan asai IgG4 untuk rTES-120 dan rTES-26 dan penggunaan penanda GST dalam 
ekspresi  dan  penulenan  protein  recombinan  toksokara.  Ujian  ini  mungkin  merupakan 
pembaharuan yang signifikan berbanding ujian komersial yang ada bagi diagnosis penyakit 
toksokariasis, terutamanya bagi negara yang ko-endemik dengan cacing tularan tanah yang 
lain. 
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CLONING, EXPRESSION AND PURIFICATION OF Toxocara canis  
RECOMBINANT ANTIGENS (rTES-26, rTES-32, rTES-120) AND DEVELOPMENT 
OF SERODIAGNOSTIC TEST FOR TOXOCARIASIS
Abstract
Routine serodiagnosis of  human toxocariasis  is  based on indirect  IgG-ELISA kits  which 
employ native  Toxocara canis excretory-secretory (TES) antigen.  However,  these  assays 
lacked  specificity  especially  when  used  in  tropical  countries  where  multiparasitism  are 
prevalent. In an effort to improve the diagnostic test for this infection, we have developed an 
IgG4-ELISA assay which uses three recombinant antigens.
In this study, recombinant  T. canis DNA which encode for rTES-26, rTES-32 and 
rTES-120 were produced by cloning of open-reading frames (ORF) of the respective genes 
via reverse-transcriptase-PCR (RT-PCR) using mRNA extracted from a culture of  T. canis 
second stage larvae into PCR2.1 TOPO vector. Sequence analysis revealed that TOPO/TES-
32  and  TOPO/TES-120  were  100% similar  to  the  reported  sequences  in  the  GenBank, 
however,  TOPO/TES-26  gene  fragment  had  four  mutations.  After  all  mutations  in 
TOPO/TES-26 gene fragments had been corrected, TES-26 and TES-32 were subsequently 
subcloned into a GST-tagged, while TES-120 was subcloned into a His-tagged prokaryotic 
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expression vector;  and all  constructs were expressed in E. coli BL21(DE3) expression host. 
The  recombinant  proteins  were  subsequently  purified  under  native  condition  by 
affinity chromatography using GST and His-Trap resins since these recombinant proteins 
were abundantly expressed in soluble form. The site-specific protease, Factor Xa, was used 
to remove GST tag in the TES-26 and TES-32 GST-tagged fusion proteins.  Western blot 
analysis  revealed  that  these  recombinant  antigens  were  immunologically  reactive  and 
specific. Sera from patients infected with toxocariasis had IgG4 antibodies that recognized 
these  recombinant  antigens,  while  sera  from individuals  with  other  infections  and  from 
healthy normals did not.
When  the  three  recombinant  antigens  were  tested  in  ELISAs  specific  for 
immunoglobulin IgM and IgE classes, and IgG subclasses (IgG1-IgG4), the results clearly 
showed that  only IgG4 assay displayed  good specificity.   The diagnostic  utility of  each 
purified recombinant antigen and rTES-30USM (previously produced in our laboratory) was 
further evaluated by IgG4-ELISA assay using  242 serum samples which included 30 sera 
from patients with clinical, haematological and serological evidence of toxocariasis. Both 
rTES-26 and rTES-32 IgG4-ELISAs demonstrated sensitivity of  80.0%; while  rTES-120 
IgG4-ELISA showed sensitivity of 93.3.0%, which is similar to that previously reported for 
rTES-30USM IgG4-ELISA.  The sensitivity of  rTES-120/rTES-30USM IgG4-ELISA was 
found to be significantly higher than rTES-26/rTES-32 IgG4-ELISA (p<0.001). However, 
the  mean  O.Ds  of  the  30  toxocariasis  samples  among  the  IgG4  assays  using  the  four 
recombinant  antigens were shown not  to be significantly different  (p>0.05).   At  p<0.05, 
there  was marginally  no significant  difference  between the  specificities  of  rTES-26 and 
rTES-120 (p=0.059), rTES-26 and rTES-30USM or between rTES-30USM and rTES-120. 
In the final assay,  rTES-32 was excluded since it was not better than rTES-26 in 
terms  of  sensitivity  or  specificity.   Instead  rTES-30USM  was  included  due  to  its  high 
sensitivity and the fact that a 100% detection of toxocariasis cases was achieved when results 
of IgG4 assays using rTES-30USM and rTES-120 were combined. 
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In summary, a final assay which is sensitive (80% to 93.3%) and specific  (92.0%-
96.2%) for detection of toxocariasis was successfully developed using three adjacent wells, 
each separately coated with rTES-26, rTES-30USM and rTES-120.  This study is novel in 
several ways namely it is the first report of the use of multiple recombinant antigens for 
serodiagnosis of toxocariasis; the use of rTES-26 (and rTES-32) in Toxocara serodiagnosis; 
the use of IgG4 assay for rTES-120 and rTES-26 and the use of  GST tag in the expression 
and  purification  of  Toxocara  recombinant  proteins.  These  test  maybe  a  significant 
improvement over commercially available tests for diagnosis of toxocariasis and may be use 




Human  toxocariasis  is  a  worldwide  parasitic  zoonosis,  caused  most  commonly  by  the 
parasite dog intestinal roundworm (Toxocara canis) and less frequently the cat roundworm 
(Toxocara cati) (Despommier, 2003; Fisher, 2003).  Although several nematodes have been 
reported  to  produce  visceral  larva  migrans  (VLM),  T.  canis appears  to  be  the  primary 
causative agent (Glickman & Schantz, 1981). T. canis is more important in causing human 
infection than T. cati because dogs are more often in direct contact with people than cats. In 
addition cats usually select sandy soil  for defecation and habitually bury  Toxocara eggs-
contaminated  faeces,  making  infectious  eggs  less  accessible  to  susceptible  individuals 
(Overgaauw,  1997;  Smith  &  Rahmah,  2006).  Nevertheless,  T.  cati has  been  implicated 
particularly in ocular toxocariasis and represents an underestimated zoonotic agent (Fisher, 
2003).  Human toxocariasis is still a poorly diagnosed disease, especially in places with low 
socioeconomic  level,  and  is  largely  unknown  to  health  professionals  and  the  general 
population (Wells,  2007). Nevertheless,  it is probably one of the most  common zoonotic 
helminthiases in temperate climates (Schantz, 1989).
24
